SSKN · As filed with the SEC
STRATA Skin Sciences income statement, by fiscal year
The statement as STRATA Skin Sciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenues, net | 30,696 | 33,562 | 33,358 | 36,161 | 29,977 | 23,090 | 31,586 | 29,855 |
| Cost of revenues | 12,815 | 14,481 | 14,897 | 14,393 | 10,127 | 8,956 | 11,316 | 12,735 |
| Gross profit | 17,881 | 19,081 | 18,461 | 21,768 | 19,850 | 14,134 | 20,270 | 17,120 |
| Operating expenses: | ||||||||
| Engineering and product development | 421 | 883 | 1,317 | 1,029 | 1,434 | 1,274 | 1,002 | 1,065 |
| Selling and marketing | 13,111 | 12,289 | 12,956 | 15,301 | 13,106 | 9,038 | 12,003 | 10,624 |
| General and administrative | 10,184 | 11,303 | 10,508 | 10,087 | 9,712 | 7,898 | 10,275 | 8,786 |
| Total operating expenses | — | — | — | — | 24,252,000 | 18,210,000 | 23,280,000 | 20,475,000 |
| Impairment of goodwill | 0 | 3,861 | 2,284 | — | — | — | — | — |
| Settlement gains | (1,135) | — | — | — | — | — | — | — |
| Total operating expenses | 22,581 | 28,336 | 27,065 | 26,417 | — | — | — | — |
| Loss from operations | (4,700) | (9,255) | (8,604) | (4,649) | (4,402) | (4,076) | (3,010) | (3,355) |
| Interest expense, net | — | — | — | — | — | (61,000) | — | — |
| Interest expense | — | — | (1,640,000) | (926,000) | (314,000) | — | (515,000) | (1,142,000) |
| Change in fair value of warrant liability | — | — | — | — | — | — | — | 0 |
| Change in fair value of embedded conversion feature | — | — | — | — | — | — | — | 0 |
| Interest expense | (1,959) | (2,107) | — | — | — | — | — | — |
| Interest income | 410 | 242 | 231 | 89 | 15 | — | — | — |
| Gain on forgiveness of debt | — | — | — | 0 | 2,029,000 | — | — | — |
| Loss on debt extinguishment | — | 0 | (909,000) | — | — | 0 | (414,000) | 0 |
| Other income, net | — | — | — | — | — | — | 0 | 200,000 |
| Other income | 0 | 864 | — | — | — | — | — | — |
| Other (expense), income net | (1,549) | (1,001) | (2,318) | (837) | 1,730 | (61) | (929) | (942) |
| Income (loss) before income taxes | — | — | — | — | — | (4,137,000) | (3,939,000) | (4,297,000) |
| Loss before (provision for) benefit from income taxes | (6,249) | (10,256) | (10,922) | (5,486) | (2,672) | — | — | — |
| (Provision for) benefit from income taxes | (12) | 170 | 92 | (63) | (34) | (275) | 149 | 264 |
| Net loss | (6,261) | (10,086) | (10,830) | (5,549) | (2,706) | (4,412) | (3,790) | (4,033) |
| Loss attributable to each class | — | — | — | — | — | — | (3,597,000) | (2,909,000) |
| Loss attributable to Preferred Series C shares | — | — | — | — | — | — | (193,000) | (1,124,000) |
| Series C Convertible Preferred Shares | — | — | — | — | — | (18,000) | — | — |
| Common Shares | — | — | — | — | (2,706,000) | — | — | — |
| Series C Convertible Preferred Stock | — | — | — | — | 0 | — | — | — |
| Net loss per share of common stock - basic (in Dollars per share) | (1.35) | (2.65) | (0.31) | — | — | (0.13) | (0.11) | (0.15) |
| Common Shares | — | — | — | (0.16) | (0.08) | — | — | — |
| Series C Convertible Preferred Stock | — | — | — | — | 0 | — | — | — |
| Net loss per share of common stock - diluted (in Dollars per share) | (1.35) | (2.65) | (0.31) | — | — | (0.13) | (0.11) | (0.15) |
| Common Shares | — | — | — | (0.16) | (0.08) | — | — | — |
| Series C Convertible Preferred Stock | — | — | — | — | 0 | — | — | — |
| Weighted average shares of common stock outstanding - basic (in Shares) | 4,650,556 | 3,807,186 | 34,920,291 | — | — | 33,609,922 | 31,978,665 | 19,589,031 |
| Common Shares | — | — | — | 34,712,246 | 34,050,274 | — | — | — |
| Series C Convertible Preferred Stock | — | — | — | — | 0 | — | — | — |
| Weighted average shares of common stock outstanding - diluted (in Shares) | 4,650,556 | 3,807,186 | 34,920,291 | — | — | 33,609,922 | 31,978,665 | 19,589,031 |
| Loss per Series C Convertible Preferred share basic and diluted (in dollars per share) | — | — | — | — | — | (48.59) | (42.24) | (55.2) |
| Shares used in computing loss per basic and diluted Series C Convertible Preferred shares (in shares) | — | — | — | — | — | 368 | 4,577 | 20,368 |
| Foreign currency translation adjustments | — | — | — | — | — | — | — | 0 |
| Comprehensive loss | — | — | — | — | — | — | — | (4,033,000) |
| Common Shares | — | — | — | 34,712,246 | 34,050,274 | — | — | — |
| Series C Convertible Preferred Stock | — | — | — | — | 0 | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.